MedTrace Logo

Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers

NCT00632008 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2010-01-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether the application of soluble beta-glucan (SBG) onto diabetic foot ulcers improves the healing of the ulcers.

Conditions

  • Chronic Diabetic Foot Ulcers

Interventions

DRUG

Soluble beta-glucan (SBG)

Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks

DRUG

Placebo comparator

Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.

Sponsors & Collaborators

  • Biotec Pharmacon ASA

    lead INDUSTRY

Principal Investigators

  • William Jeffcoate, MD, PhD · Nottingham City Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-08-31
Completion
2009-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00632008 on ClinicalTrials.gov